Assessment of the reduced injection pain of the newly developed formation of the rocuronium

Assessment of the reduced injection pain of the newly developed formation of the rocuronium - Assessment of injection pain of rocuronium

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022300

Enrollment

150

Registered

2016-05-20

Start date

2017-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients requiring general anesthesia

Interventions

After the induction of general anesthesia, newly developed form of roculonium (0.9mg/Kg) will be injected intravenously. After the induction of general anesthesia, eslax (0.9mg/Kg) will be injected

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who will receive elective surgery under general anesthesia and obtained written informed consent about this study.

Exclusion criteria

Exclusion criteria: Muscular disease Known allergy against eslax, propofol Muscle weakness of upper arm Obesity (BMI>30%)

Design outcomes

Primary

Measure	Time frame
frequency of the withdrawal response of upper arm 3 minutes after the drug injection.	—

Secondary

Measure	Time frame
magnitude of the withdrawal response, change of blood pressure and heart rate 3 minutes after the drug injection.	—

Countries

Japan

Contacts

Public ContactFumimasa Amaya

Kyoto Prefectural University of Medicine Department of Anesthesiology

ama@koto.kpu-m.ac.jp075-251-5633

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026